Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
hu14.18K322A plus irinotecan and temozolomide in high-risk neuroblastoma
2025-524397-42-00Phase 3Authorised
- Sponsor
- Renaissance Pharma
- Start
- Sep 2026
- Modality
- Small Molecules, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 9
01
Overview
Phase 3, open-label trial of daretabart, irinotecan and temozolomide in neuroblastoma (2 arms), sponsored by Renaissance Pharma. Primary endpoints: Overall response rate and Metastatic complete response rate. Planned start Sep 2026; status: authorised.
02
Drugs
daretabartirinotecantemozolomide
03
Conditions
neuroblastoma
Beyond the preview
Go deeper on 2025-524397-42-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-524397-42-00.